IRIS
MORGILLO, Floriana
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 12.272
NA - Nord America 5.770
AS - Asia 4.945
SA - Sud America 680
AF - Africa 66
OC - Oceania 13
Continente sconosciuto - Info sul continente non disponibili 6
Totale 23.752
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 7.903
US - Stati Uniti d'America 5.651
SG - Singapore 1.621
IE - Irlanda 1.196
CN - Cina 1.080
IT - Italia 953
HK - Hong Kong 812
VN - Vietnam 617
BR - Brasile 583
DE - Germania 467
GB - Regno Unito 455
UA - Ucraina 403
FR - Francia 293
KR - Corea 253
FI - Finlandia 157
SE - Svezia 143
TR - Turchia 137
IN - India 136
GR - Grecia 98
JP - Giappone 92
CA - Canada 66
NL - Olanda 45
AR - Argentina 38
AT - Austria 38
PK - Pakistan 37
BD - Bangladesh 34
MX - Messico 29
BE - Belgio 24
ID - Indonesia 21
ES - Italia 17
IQ - Iraq 17
PL - Polonia 17
ZA - Sudafrica 14
EC - Ecuador 13
CH - Svizzera 12
CL - Cile 12
CO - Colombia 11
PH - Filippine 11
CZ - Repubblica Ceca 10
KE - Kenya 9
AE - Emirati Arabi Uniti 8
VE - Venezuela 8
AU - Australia 7
HU - Ungheria 7
IR - Iran 7
MA - Marocco 7
SA - Arabia Saudita 7
TN - Tunisia 7
TW - Taiwan 7
UZ - Uzbekistan 7
EG - Egitto 6
NZ - Nuova Zelanda 6
PY - Paraguay 6
AO - Angola 5
AZ - Azerbaigian 5
CR - Costa Rica 5
DZ - Algeria 5
EU - Europa 5
IL - Israele 5
LT - Lituania 5
AL - Albania 4
DO - Repubblica Dominicana 4
JO - Giordania 4
MK - Macedonia 4
NP - Nepal 4
OM - Oman 4
PE - Perù 4
TH - Thailandia 4
TT - Trinidad e Tobago 4
JM - Giamaica 3
KZ - Kazakistan 3
MY - Malesia 3
RO - Romania 3
SN - Senegal 3
UY - Uruguay 3
BO - Bolivia 2
CG - Congo 2
GA - Gabon 2
HN - Honduras 2
HR - Croazia 2
LK - Sri Lanka 2
LU - Lussemburgo 2
LV - Lettonia 2
PA - Panama 2
PT - Portogallo 2
RS - Serbia 2
SK - Slovacchia (Repubblica Slovacca) 2
SV - El Salvador 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BW - Botswana 1
BY - Bielorussia 1
GT - Guatemala 1
IS - Islanda 1
KG - Kirghizistan 1
KW - Kuwait 1
ML - Mali 1
MU - Mauritius 1
Totale 23.742
Salva come PNG Salva come JPEG
Città #
Moscow 2.854
Dublin 1.188
San Jose 814
Hong Kong 797
Singapore 709
Chandler 662
Santa Clara 639
Jacksonville 633
Ashburn 267
Seoul 231
Ho Chi Minh City 194
Naples 192
Beijing 186
Princeton 164
Bremen 162
New York 152
Hanoi 139
Medford 129
Ann Arbor 128
Hefei 125
Roxbury 125
Dallas 124
Caserta 119
Munich 106
Los Angeles 87
Wilmington 87
Bengaluru 86
The Dalles 79
São Paulo 62
Boardman 59
Nanjing 56
San Mateo 46
Woodbridge 45
Cambridge 44
Haiphong 39
Da Nang 38
Turku 38
Des Moines 37
Napoli 34
Milan 32
Council Bluffs 29
Nuremberg 29
Elora 28
Houston 28
Amsterdam 25
Brussels 24
Dong Ket 24
Rio de Janeiro 23
Jinan 22
Orem 22
Rome 22
Vienna 21
Helsinki 18
Mountain View 18
Atlanta 17
Tianjin 17
Brooklyn 16
Nanchang 16
Brasília 15
Chicago 15
Istanbul 15
Shanghai 15
Aiello Del Sabato 14
Aversa 14
London 14
Tokyo 14
Düsseldorf 13
Frankfurt am Main 13
Warsaw 13
Afragola 12
Belo Horizonte 12
Curitiba 12
Norwalk 12
Ercolano 11
Hải Dương 11
Mumbai 11
Ninh Bình 11
Piscataway 11
Zhengzhou 11
Guarulhos 10
Lappeenranta 10
Toronto 10
Auburn Hills 9
Boston 9
Brno 9
Falkenstein 9
Hangzhou 9
Thái Bình 9
Bahawalpur 8
Chennai 8
Columbus 8
Guangzhou 8
Jakarta 8
Nairobi 8
Seattle 8
Shenyang 8
Thái Nguyên 8
Biên Hòa 7
Bến Tre 7
Can Tho 7
Totale 12.553
Salva come PNG Salva come JPEG
Nome #
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 248
ONCOLOGIA MEDICA 206
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 205
A Multicenter, Open-Label Phase II Study of Metformin With Erlotinib in Second-Line Therapy of Stage IV Non-Small-Cell Lung Cancer Patients: Treatment Rationale and Protocol Dynamics of the METAL Trial. 205
Adequacy of Cytologic Samples by Ultrasound-Guided Percutaneous Transthoracic Fine-Needle Aspiration Cytology of Peripheral Pulmonary Nodules for Morphologic Diagnosis and Molecular Evaluations: Comparison With Computed Tomography-Guided Percutaneous Transthoracic Fine-Needle Aspiration Cytology 196
AXL is an oncotarget in human colorectal cancer 195
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 192
A trimodality, four-step treatment including chemotherapy, pleurectomy/decortication and radiotherapy in early-stage malignant pleural mesothelioma: A single-institution retrospective case series study 186
Effect of preoperative chemoradiotherapy on outcome of patients with locally advanced esophagogastric junction adenocarcinoma—a pilot study. Curr Oncol 21, 3, june 2014 125-133 185
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 185
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 184
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 183
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 181
Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: A propensity score-matched analysis 176
Immunotherapy for head and neck cancer: Present and future 174
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 173
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 173
Chronic inflammation and oxidative stress in human carcinogenesis 171
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 167
A randomized phase II study of pemetrexed or RAD001 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: treatment rationale and protocol dynamics 166
Elevated perioperative serum vascular endothelial growth factor levels in patients with colon carcinoma. 165
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 163
Cisplatin in addition to single-agent first-line chemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC): efficacy results of a joint analysis of the multicentre, randomized phase 3 MILES-3 and MILES-4 studies 163
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 162
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 161
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 160
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 159
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 159
Adjuvant treatment with EGFR TKI in resected non-small cell lung cancer with EGFR mutation: all that glitters is not gold! 159
A Critical Issue in Lung Cancer Cytology and Small Biopsies: DNA and RNA Extraction from Archival Stained Slides for Biomarker Detection through Real Time PCR and NGS-The Experience in Pathological Anatomy Unit 159
CARdioimaging in Lung Cancer PatiEnts Undergoing Radical RadioTherapy: CARE-RT Trial 158
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 158
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 156
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 155
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 153
Conversion chemotherapy followed by epatic resection in colorectal cancer with initially unresectable liver-limited metastases 152
Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer 151
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 151
AXL and MET Tyrosine Kinase Receptors Co-Expression as a Potential Therapeutic Target in Malignant Pleural Mesothelioma 150
Control of post-thoracotomy pain by transcutaneous electrical nerve stimulation: effect on serum cytokine levels, visual analogue scale, pulmonary function and medication(dagger) 150
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 149
Addition of Bevacizumab to Erlotinib as First-Line Treatment of Patients With EGFR-Mutated Advanced Nonsquamous NSCLC: The BEVERLY Multicenter Randomized Phase 3 Trial 147
Carcinogenesis as a Result of Multiple Inflammatory and Oxidative Hits: a Comprehensive Review from Tumor Microenvironment to Gut Microbiota 147
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 146
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 145
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 145
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 145
Serum insulin-like growth factor 1 correlates with the risk of nodal metastasis in endocrine-positive breast cancer 145
Inherited predisposition to malignant mesothelioma: germline BAP1 mutations and beyond 145
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 144
Pimasertib hydrochloride 143
Addition of metformin to anti-PD-1/PD-L1 drugs activates anti- tumor immune response in peripheral immune cells of NSCLC patients 141
The value of matrix metalloproteinase-9 and vascular endothelial growth factor receptor 1 pathway in diagnosing indeterminate pleural effusion. 140
Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs 140
Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis 140
Farmacogenomica e cancro colorettale 139
PercuTwist tracheostomy in an intubated patient with tracheal stent 139
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 139
Discovery of N-Substituted-2-Oxoindolin Benzoylhydrazines as c-MET/SMO Modulators in EGFRi-Resistant Non-Small Cell Lung Cancer 138
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 138
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 135
Complete response to preoperative chemoradiation and survival in esophageal cancer : a pooled analysis of three singe-institution phase II trials. 135
Vedolizumab as Rescue Therapy in Carboplatin-Gemcitabine-Induced Triggered Acute Severe Ulcerative Colitis Flare-Up 134
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 134
Combined Therapeutic Strategies Based on the Inhibition of Non-Oncogene Addiction to Improve Tumor Response in EGFR- and KRAS-Mutant Non-Small-Cell Lung Cancer 132
Vascular endothelial growth factor in pleural fluid for differential diagnosis of benign and malignant origin and its clinical applications. 131
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 130
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 130
AXL, c-MET and VEGFR2 Tyrosine Kinase Receptors as Therapeutic Targets in Malignant Pleural Mesothelioma 130
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 129
Double-staining Immunohistochemistry Reveals in Malignant Pleural Mesothelioma the Coexpression of ERCC1 and RRM1 as a Frequent Biological Event Related to Poorer Survival 129
Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent antitumor activity with reduced anthracyclina-induced cardiotoxicity (review) 128
TRASTUZUMAB RESISTANCE IN BREAST CANCER 128
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 128
Serum vascular endothelial growth factor (VEGF)levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer 127
Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: Relationship with prognosis 127
First-Line Erlotinib Followed by Second-Line Cisplatin- Gemcitabine Chemotherapy in Advanced Non–Small-Cell Lung Cancer: The TORCH Randomized Trial 126
Phosphatidylinositol 3-kinase (PI3Ka)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells 126
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 124
Targeting EGFR in Pancreatic Cancer Treatment. 123
Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: Case report and translational study 123
PET-TC BODY CON FDG IN ONCOLOGIA 122
Cetuximab and gemcitabine in elderly or adult PS2 patients with advanced non-small-cell lung cancer: The cetuximab in advanced lung cancer (CALC1-E and CALC1-PS2) randomized phase II trials 121
Trimodality treatment in early-stage malignant pleural mesothelioma. Preliminary results of a multicenter phase II trial 121
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 121
Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: a pooled analysis of 6 randomized trials 121
Post- operative xelox and chemoradiation in stage III-IV radically resected gastric cancer patients: preliminary results of a pilot study. 119
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 119
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 118
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 118
Rescue Surgery for Advanced Stage Lung Cancer: A Systematic Review 117
Combination of epidermal growth factor receptor inhibitors and antiangiogenic drugs: a model for treatment 117
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 116
Immune-Cell-Derived Exosomes as a Potential Novel Tool to Investigate Immune Responsiveness in SCLC Patients: A Proof-of-Concept Study 115
Treatment of Advanced Non-Small-Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation or ALK Gene Rearrangement: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology. 115
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation 115
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 115
The prognostic value of histopathology in invasive lung adenocarcinoma: a comparative review of the main proposed grading systems 114
Preoperative chemo-radiotherapy for carcinoma of the esophagus 114
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 114
Totale 14.691
Salva come PNG Salva come JPEG
Categoria #
all - tutte 81.225
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 81.225
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202163 0 0 0 0 0 0 0 0 0 0 0 63
2021/20221.185 56 17 24 28 374 17 45 45 49 101 107 322
2022/20232.502 253 65 39 245 311 203 11 146 1.115 19 49 46
2023/2024935 82 34 43 55 291 132 18 26 16 18 74 146
2024/20253.049 33 62 30 77 453 402 397 261 438 412 260 224
2025/202613.444 516 605 653 619 1.053 7.361 781 733 487 361 179 96
Totale 24.238